On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice

Toxicologic Pathology

Volumn 41, Issue 2, 2013, Pages 303-309

  Rosol, Thomas J ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

adenoma; C cell; calcitonin; GLP 1; GLP 1 receptor; glucagon like peptide 1; hyperplasia; thyroid gland

Indexed keywords

ALBIGLUTIDE; ARFORMOTEROL; ATENOLOL; CALCITONIN; CARCINOGEN; COLESEVELAM; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; NARATRIPTAN; PALONOSETRON;

ADJUVANT THERAPY; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CALCITONIN BLOOD LEVEL; CARCINOGENESIS; CELL HYPERPLASIA; CELL PROLIFERATION; DECREASED APPETITE; DRUG APPROVAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CARCINOGENICITY; DRUG EFFECT; DRUG HALF LIFE; GLUCAGON RELEASE; GLUCONEOGENESIS; HEART PROTECTION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INSULIN SENSITIVITY; MORPHOMETRICS; MOUSE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOLYSIS; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTO ONCOGENE; RAT; STOMACH EMPTYING; THYROID MEDULLARY CARCINOMA; THYROID PARAFOLLICULAR CELL;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERPLASIA; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; MICE; PEPTIDES; RATS; RECEPTORS, GLUCAGON; THYROID GLAND; THYROID NEOPLASMS; VENOMS;

HELODERMATIDAE; MUS; PRIMATES; RATTUS; RODENTIA;

EID: 84875702681     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623312472402     Document Type: Article

References (45)

1. Axelsen L. N., Keung W., Pedersen H. D., Meier E., Riber D., Kjolbye A. L., Petersen J. S., Proctor S. D., Holstein-Rathlou N. H., Lopaschuk G. D.. Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts. Brit J Pharmacol. 2012 ; 165: 2736-48
2. Baggio L. L., Drucker D. J.. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007 ; 132: 2131-57
3. Barnett A. H.. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: Guidance from studies of liraglutide. Diabetes, Obes Metab. 2012 ; 14: 304-14
4. Bjerre Knudsen L., Madsen L. W., Andersen S., Almholt K., de Boer A. S., Drucker D. J., Gotfredsen C., Egerod F. L., Hegelund A. C., Jacobsen H., Jacobsen S. D., Moses A. C., Molck A. M., Nielsen H. S., Nowak J., Solberg H., Thi T. D., Zdravkovic M., Moerch U.. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010 ; 151: 1473-86
5. Boyce J. T., Boyce R. W., Gundersen H. J.. Choice of morphometric methods and consequences in the regulatory environment. Toxicol Pathol. 2010 ; 38: 1128-33
6. Boyce R. W., Dorph-Petersen K. A., Lyck L., Gundersen H. J.. Design-based stereology: Introduction to basic concepts and practical approaches for estimation of cell number. Toxicol Pathol. 2010 ; 38: 1011-25
7. Bullock B. P., Heller R. S., Habener J. F.. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996 ; 137: 2968-78
8. Capen C. C. Jubb, Kennedy, and Palmer's Pathology of Domestic Animals. Maxie G. M., ed. Philadelphia, PA: Saunders Elsevier ; 2007: 325-428.
9. Capen C. C., Martin S. L.. The effects of xenobiotics on the structure and function of thyroid follicular and C-cells. Toxicol Pathol. 1989 ; 17: 266-93
10. Chiu W. Y., Shih S. R., Tseng C. H.. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer. Exp Diabetes Res. 2012 ; 2012: 924168
11. De Miguel M., Fernandez-Santos J. M., Trigo-Sanchez I., Matera I., Ceccherini I., Martin I., Romeo G., Galera-Davidson H.. The Ret proto-oncogene in the WAG/Rij rat strain: An animal model for inherited C-cell carcinoma?. Lab Anim. 2003 ; 37: 215-21
12. Dunphy J. L., Taylor R. G., Fuller P. J.. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol. 1998 ; 141: 179-86
13. Eng J., Kleinman W. A., Singh L., Singh G., Raufman J. P.. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992 ; 267: 7402-405
14. Feitsma H., Cuppen E.. Zebrafish as a cancer model. Mol Cancer Res: MCR. 2008 ; 6: 685-94
15. Filipovic B., Jurjevic B. S., Stojanoski M. M., Nestorovic N., Milosevic V., Sekulic M.. The effect of chronic calcium treatment on thyroid C cells in ovariectomized rats. Life Sci. 2005 ; 77: 121-29
16. Flint A., Kapitza C., Hindsberger C., Zdravkovic M.. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther. 2011 ; 28: 213-26
17. Furman B. L.. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon. 2012 ; 59: 464-71
18. Garber A. J.. Novel GLP-1 receptor agonists for diabetes. Expert Op Invest Drugs. 2012 ; 21: 45-57
19. Gier B., Butler P. C., Lai C. K., Kirakossian D., DeNicola M. M., Yeh M. W.. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012 ; 9: 121-3
20. Gupta R., Walunj S. S., Tokala R. K., Parsa K. V., Singh S. K., Pal M.. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 ; 10: 71-87
21. Hegedus L., Moses A. C., Zdravkovic M., Le Thi T., Daniels G. H.. GLP-1 and calcitonin concentration in humans: Lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011 ; 96: 853-60
22. JoffeH.ParksM.ParolaA.MahoneyK.DerrJ. (2009). Liraglutide, FDA Briefing Materials for the Endocrinologic and Metabolic Drugs Advisory Committee Meeting, April 2, 2009. Accessed August 19, 2012. http://www.fda.gov/ohrms/dockets/ac/ 09/briefing/2009-4422b2-01-FDA.pdf.
23. Kameda Y.. Distribution of C cells in monkey thyroid glands as studied by the immunoperoxidase method using anti-calcitonin and anti-C-thyroglobulin antisera. Archivum histologicum Japonicum. 1983 ; 46: 221-28
24. Kanoski S. E., Rupprecht L. E., Fortin S. M., De Jonghe B. C., Hayes M. R.. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology. 2012 ; 62: 1916-27
25. La Perle K. M., Jhiang S. M., Capen C. C.. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Amer J Pathol. 2000 ; 157: 671-77
26. Lovshin J. A., Drucker D. J.. Incretin-based therapies for type 2 diabetes mellitus. Nature reviews. Endocrinology. 2009 ; 5: 262-69
27. Madsen L. W., Knauf J. A., Gotfredsen C., Pilling A., Sjogren I., Andersen S., Andersen L., de Boer A. S., Manova K., Barlas A., Vundavalli S., Nyborg N. C., Knudsen L. B., Moelck A. M., Fagin J. A.. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology. 2012a ; 153: 1538-47
28. Madsen L. W., Knauf J. A., Gotfredsen C., Pilling A., Sjogren I., Andersen S., Andersen L., de Boer A. S., Manova K., Barlas A., Vundavalli S., Nyborg N. C. B., Knudsen L. B., Moelck A. M., Fagin J. A.. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology. 2012b ; 153: 1538-47
29. Martin-Lacave I., Conde E., Montero C., Galera-Davidson H.. Quantitative changes in the frequency and distribution of the C-cell population in the rat thyroid gland with age. Cell Tis Res. 1992 ; 270: 73-77
30. Mells J. E., Fu P. P., Sharma S., Olson D., Cheng L., Handy J. A., Saxena N. K., Sorescu D., Anania F. A.. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Amer J Physiol Gastrointestinal Liver Physiol. 2012 ; 302: G225-35
31. Okada H., Merryman J. I., Rosol T. J., Capen C. C.. Effects of humoral hypercalcemia of malignancy and gallium nitrate on thyroid C-cells in nude mice: Immunohistochemical and ultrastructural investigations. Vet Pathol. 1994 ; 31: 349-57
32. Rosol T. J., Capen C. C.. Biology of disease: Mechanisms of cancer-induced hypercalcemia. Lab Invest. 1992 ; 67: 680-702
33. Rosol T. J., Capen C. C.. Pathophysiology of calcium, phosphorus, and magnesium metabolism in animals. Vet Clin NA: Sm An Pract. 1996 ; 26: 1155-84
34. Rosol T. J., Capen C. C. Clinical Biochemistry of Domestic Animals. Kaneko J. J. Harvey J. W. Bruss M. L., ed. San Diego, CA: Academic Press ; 1997: 619-702.
35. Rourke K. M., Kohn C. W., Levine A. L., Rosol T. J., Toribio R. E.. Rapid calcitonin response to experimental hypercalcemia in healthy horses. Domest Anim Endocrinol. 2009 ; 36: 197-201
36. Schenck P. A., Chew D. J., Nagode L. A., Rosol T. J. Fluid Therapy in Small Animal Practice. DiBartola S. P., ed. Philadelphia, PA: WB Saunders ; 2010: 122-194.
37. Scrocchi L. A., Brown T. J., MaClusky N., Brubaker P. L., Auerbach A. B., Joyner A. L., Drucker D. J.. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 1996 ; 2: 1254-58
38. Thorens B., Porret A., Buhler L., Deng S. P., Morel P., Widmann C.. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes. 1993 ; 4: 1678-8
39. Triggs S. M., Williams E. D.. Experimental carcinogenesis in the thyroid follicular and C cells. A comparison of the effect of variation in dietary calcium and of radiation. Acta Endocrinol (Copenh). 1977 ; 85: 84-92
40. Velasquez D. A., Beiroa D., Vazquez M. J., Romero A., Lopez M., Dieguez C., Nogueiras R.. Central GLP-1 actions on energy metabolism. Vitam Horm. 2010 ; 84: 303-17
41. Vitale G., Ciccarelli A., Caraglia M., Galderisi M., Rossi R., Del Prete S., Abbruzzese A., Lupoli G.. Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: Omeprazole vs pentagastrin. Clin Chem. 2002 ; 4: 1505-1
42. Whalley N. M., Pritchard L. E., Smith D. M., White A.. Processing of proglucagon to GLP-1 in pancreatic alpha-cells: Is this a paracrine mechanism enabling GLP-1 to act on beta-cells?. J Endocrinol. 2011 ; 211: 99-106
43. Willard F. S., Sloop K. W.. Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor. Exp Diabetes Res. 2012 ; 2012 ( 470851 ):
44. Yabe D., Seino Y.. Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and beta cell preservation. Prog Biophys Mol Biol. 2011 ; 107: 248-56
45. Yamada C., Yamada Y., Tsukiyama K., Yamada K., Udagawa N., Takahashi N., Tanaka K., Drucker D. J., Seino Y., Inagaki N.. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008 ; 149: 574-79